In the span of less than 12 hours last week, the Trump administration took two seemingly contradictory actions that could have profound effects on the insurance marketplaces set up by the Affordable Care Act.
Three months after President Donald Trump announced his blueprint to bring down drug prices, administration officials have begun putting some teeth behind the rhetoric.
Oregon U.S. Sen. Ron Wyden again blasted the Trump administration on Monday over its proposed drug pricing plan.
President Donald Trump has insisted for months that “Obamacare is already dead.”
If President Donald Trump were to follow through on his threats to cut federal cost-sharing subsidies, health insurance premiums for silver plans would soar by an average of 20 percent next year and the federal deficit would rise by $194 billion over the next decade, the nonpartisan Congressional
President Donald Trump, who appears increasingly frustrated by congressional Republicans’ inability to “repeal and replace” the Affordable Care Act, has led — since before he took office — the ballyhoo to let the law fail.
The pharmaceutical industry could see windfall profits from a little-noticed tweak to the insurance market tucked into the Trump administration’s draft executive order on drug prices, experts say.
With their party gaining control of both the White House and Congress, some Republican voters are growing hesitant about outright abolition of the Affordable Care Act and instead favoring a more circumspect approach of scaling it back, according to a poll released Thursday.
